MedPath

Low-calorie Diet and Body Composition Prior to Roux-en-Y Gastric Bypass

Not Applicable
Completed
Conditions
Morbid Obesity
Liver Fat
Registration Number
NCT02144597
Lead Sponsor
Imperial College London
Brief Summary

Losing weight before undergoing Roux-en-Y gastric bypass (RYGB) surgery may reduce liver fat content and size thereby improving surgical outcomes. This study aims to investigate whether a 2-week or 6-week pre-operative liquid formula low-calorie diet (LCD) reduces liver fat further than a conventional food diet prior to RYGB using magnetic resonance imaging (MRI). The hypothesis is that the 2-week and 6-week liquid formula LCD will reduce liver fat further than the conventional food pre-operative diet.

Detailed Description

The morbidly obese subjects (BMI higher then 40 kg/m2) were randomised and assessed at baseline (week 0). After 2 weeks on a low-calorie diet (LCD), participants underwent either Roux-en-Y gastric bypass (RYGB) or continued with a LCD for 4 weeks.The participants will reassess at week 6.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • patients undergoing Roux-en-Y gastric bypass at Imperial Weight Centre
  • aged 18 to 60 years
  • boby mass index of 35 to 55 kg/m2
Exclusion Criteria
  • Claustrophobia
  • Pacemaker, metal implant, clips, implanted device, shrapnel or bullets, metal in eyes that precludes magnetic resonance imaging
  • Current pregnancy or breast feeding for females (as determined by a pregnancy test)
  • A full term pregnancy within the last year for females
  • Treatment with any medication that might affect the study outcomes
  • Haemorrhagic disorders and anticoagulant treatment
  • History of cancer, excluding skin cancer
  • History of severe or multiple allergies, severe adverse drug reaction or leucopenia
  • Smokers
  • Regular drinkers of more than three units of alcohol daily
  • History of, or current evidence of, abuse of alcohol or any drug substance, licit or illicit
  • Regular intake of over-the-counter (OTC) medication (other than the occasional paracetamol/aspirin)
  • Poor compliers or subjects unlikely to commit to the 26 week study duration
  • Blood donation within the 12 week period before the initial study dose
  • Use of monoamine oxidase inhibitors (MAOIs) as anti depressant

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change in Intra-hepatocellular Lipid Content (IHCL) Following the Pre-operative Dietat 2 weeks or 6 weeks depending on group

Intra-hepatocellular lipid content will be measured by magnetic resonance spectroscopy

Secondary Outcome Measures
NameTimeMethod
Operative Timeat the time of surgery

The operative time will be recorded at the time of surgery by the operating surgeon (either after 2 weeks for the Control group and 2-week LCD group or after 6 weeks for the 6-week LCD group)

Change in Intra-hepatocellular Lipid Content (IHCL) Following Roux-en-Y Gastric Bypassat 6 months following Roux-en-Y gastric bypass

Intra-hepatocellular lipid content (IHCL) will be compared between groups at 6 months following Roux-en-Y gastric bypass

Complexity of Surgeryat the time of surgery

Complexity of surgery will be assessed by the surgeon at the time of surgery (either after 2 weeks for the Control group and 2-week LCD group or after 6 weeks for the 6-week LCD group) The complexity of the surgery was assessed through a score on a complexity scale based on questionnaires previously published by Anders Thorell"s and David Edholm"s groups (Edholm et al., 2011, Van Nieuwenhove et al., 2011). The scores (1-5) for 7 variables: exposure, bleeding, difficulty in dissection, difficulty in reconstruction, surgical judgment, technical demand and psychological stress were combined into a complexity of surgery score with a minimum of 7 (very little complexity) and a maximum of 35 (very high complexity).

Trial Locations

Locations (1)

Imperial Clinical research facility

🇬🇧

London, Greater London, United Kingdom

Imperial Clinical research facility
🇬🇧London, Greater London, United Kingdom

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.